CD276 and acute myeloid leukemia: AML patients showing a higher expression level of LAIR1, CD276, LGALS9, PDCD1, PDCD1L2G, and TNFSF14 experienced worse prognosis; thus, indicating that targeting these immune checkpoints may be beneficial for treating high-risk AML patients.